Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8640188 | 0.79 | CTSL (0.57) | CTSLCTSBCTSKEPHX2JAK2 | |
| SCHEMBL2700673 | 0.79 | CTSL (0.57) | CTSLCTSBCTSKEPHX2JAK2 | |
| SCHEMBL11814690 | 0.79 | CTSL (0.57) | CTSLCTSBCTSKEPHX2JAK2 | |
| SCHEMBL22449348 | 0.79 | CTSL (0.57) | CTSLCTSBCTSKEPHX2JAK2 | |
| SCHEMBL22449352 | 0.78 | CTSL (0.46) | CTSLCTSBCTSKEPHX2JAK2 | |
| SCHEMBL20093737 | 0.78 | CTSL (0.46) | CTSLCTSBCTSKEPHX2JAK2 | |
| SCHEMBL18434985 | 0.77 | CTSL (0.47) | CTSLCTSBCTSKEPHX2JAK2 | |
| SCHEMBL18678556 | 0.77 | CTSL (0.44) | CTSLCTSBCTSKEPHX2JAK2 | |
| SCHEMBL18669503 | 0.77 | CTSL (0.44) | CTSLCTSBCTSKEPHX2JAK2 | |
| SCHEMBL15359269 | 0.76 | CTSL (0.43) | CTSLCTSBCTSKEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | CTSL 4385/4885CTSB 1603/4885CTSK 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.